Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.

BACKGROUND:In 1980, human diploid cell vaccine (HDCV, Imovax Rabies, Sanofi Pasteur), was licensed for use in the United States. OBJECTIVE:To assess adverse events (AEs) after HDCV reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. METHODS...

Full description

Bibliographic Details
Published in:PLOS Neglected Tropical Diseases
Main Authors: Pedro L Moro, Emily Jane Woo, Wendy Paul, Paige Lewis, Brett W Petersen, Maria Cano
Format: Article in Journal/Newspaper
Language:English
Published: Public Library of Science (PLoS) 2016
Subjects:
Online Access:https://doi.org/10.1371/journal.pntd.0004846
https://doaj.org/article/9d45a743714f4276818fb02b53d2e66e
id ftdoajarticles:oai:doaj.org/article:9d45a743714f4276818fb02b53d2e66e
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:9d45a743714f4276818fb02b53d2e66e 2023-05-15T15:08:59+02:00 Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015. Pedro L Moro Emily Jane Woo Wendy Paul Paige Lewis Brett W Petersen Maria Cano 2016-07-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0004846 https://doaj.org/article/9d45a743714f4276818fb02b53d2e66e EN eng Public Library of Science (PLoS) http://europepmc.org/articles/PMC4943633?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0004846 https://doaj.org/article/9d45a743714f4276818fb02b53d2e66e PLoS Neglected Tropical Diseases, Vol 10, Iss 7, p e0004846 (2016) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2016 ftdoajarticles https://doi.org/10.1371/journal.pntd.0004846 2022-12-31T08:17:08Z BACKGROUND:In 1980, human diploid cell vaccine (HDCV, Imovax Rabies, Sanofi Pasteur), was licensed for use in the United States. OBJECTIVE:To assess adverse events (AEs) after HDCV reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. METHODS:We searched VAERS for US reports after HDCV among persons vaccinated from January 1, 1990-July 31, 2015. Medical records were requested for reports classified as serious (death, hospitalization, prolonged hospitalization, disability, life-threatening-illness), and those suggesting anaphylaxis and Guillain-Barré syndrome (GBS). Physicians reviewed available information and assigned a primary clinical category to each report using MedDRA system organ classes. Empirical Bayesian (EB) data mining was used to identify disproportional AE reporting after HDCV. RESULTS:VAERS received 1,611 reports after HDCV; 93 (5.8%) were serious. Among all reports, the three most common AEs included pyrexia (18.2%), headache (17.9%), and nausea (16.5%). Among serious reports, four deaths appeared to be unrelated to vaccination. CONCLUSIONS:This 25-year review of VAERS did not identify new or unexpected AEs after HDCV. The vast majority of AEs were non-serious. Injection site reactions, hypersensitivity reactions, and non-specific constitutional symptoms were most frequently reported, similar to findings in pre-licensure studies. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Pasteur ENVELOPE(140.099,140.099,-66.625,-66.625) Barré ENVELOPE(-68.550,-68.550,-67.500,-67.500) PLOS Neglected Tropical Diseases 10 7 e0004846
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
spellingShingle Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
Pedro L Moro
Emily Jane Woo
Wendy Paul
Paige Lewis
Brett W Petersen
Maria Cano
Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.
topic_facet Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
description BACKGROUND:In 1980, human diploid cell vaccine (HDCV, Imovax Rabies, Sanofi Pasteur), was licensed for use in the United States. OBJECTIVE:To assess adverse events (AEs) after HDCV reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. METHODS:We searched VAERS for US reports after HDCV among persons vaccinated from January 1, 1990-July 31, 2015. Medical records were requested for reports classified as serious (death, hospitalization, prolonged hospitalization, disability, life-threatening-illness), and those suggesting anaphylaxis and Guillain-Barré syndrome (GBS). Physicians reviewed available information and assigned a primary clinical category to each report using MedDRA system organ classes. Empirical Bayesian (EB) data mining was used to identify disproportional AE reporting after HDCV. RESULTS:VAERS received 1,611 reports after HDCV; 93 (5.8%) were serious. Among all reports, the three most common AEs included pyrexia (18.2%), headache (17.9%), and nausea (16.5%). Among serious reports, four deaths appeared to be unrelated to vaccination. CONCLUSIONS:This 25-year review of VAERS did not identify new or unexpected AEs after HDCV. The vast majority of AEs were non-serious. Injection site reactions, hypersensitivity reactions, and non-specific constitutional symptoms were most frequently reported, similar to findings in pre-licensure studies.
format Article in Journal/Newspaper
author Pedro L Moro
Emily Jane Woo
Wendy Paul
Paige Lewis
Brett W Petersen
Maria Cano
author_facet Pedro L Moro
Emily Jane Woo
Wendy Paul
Paige Lewis
Brett W Petersen
Maria Cano
author_sort Pedro L Moro
title Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.
title_short Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.
title_full Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.
title_fullStr Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.
title_full_unstemmed Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.
title_sort post-marketing surveillance of human rabies diploid cell vaccine (imovax) in the vaccine adverse event reporting system (vaers) in the united states, 1990‒2015.
publisher Public Library of Science (PLoS)
publishDate 2016
url https://doi.org/10.1371/journal.pntd.0004846
https://doaj.org/article/9d45a743714f4276818fb02b53d2e66e
long_lat ENVELOPE(140.099,140.099,-66.625,-66.625)
ENVELOPE(-68.550,-68.550,-67.500,-67.500)
geographic Arctic
Pasteur
Barré
geographic_facet Arctic
Pasteur
Barré
genre Arctic
genre_facet Arctic
op_source PLoS Neglected Tropical Diseases, Vol 10, Iss 7, p e0004846 (2016)
op_relation http://europepmc.org/articles/PMC4943633?pdf=render
https://doaj.org/toc/1935-2727
https://doaj.org/toc/1935-2735
1935-2727
1935-2735
doi:10.1371/journal.pntd.0004846
https://doaj.org/article/9d45a743714f4276818fb02b53d2e66e
op_doi https://doi.org/10.1371/journal.pntd.0004846
container_title PLOS Neglected Tropical Diseases
container_volume 10
container_issue 7
container_start_page e0004846
_version_ 1766340237569556480